Identification of photodegradation product of amisulpride by ultra-high-pressure liquid chromatography-DAD/ESI-quadrupole time-of-flight-mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 5, 2011, Pages 904-910

  Skibiński, Robert ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Amisulpride; Photodegradation; Q TOF; UHPLC; UVA irradiation

Indexed keywords

AMISULPRIDE;

ACCURACY; ARTICLE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STRUCTURE; ELECTROSPRAY; ELECTROSPRAY IONIZATION QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHOTODEGRADATION; PRIORITY JOURNAL; ULTRA HIGH PRESSURE LIQUID CHROMATOGRAPHY DAD;

ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; PHOTOCHEMISTRY; SULPIRIDE; TANDEM MASS SPECTROMETRY;

EID: 80052813221     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.07.030     Document Type: Article

References (27)

1. Mortimer A.M. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int. J. Neuropsychopharmacol. 2004, 7:21-25.
2. Amore M., Jori M.C. Faster response on amisulpride 50mg versus sertraline 50-100mg in patients with dysthymia or double depression: a randomized double-blind, parallel group study. Int. Clin. Psychopharmacol. 2001, 16:317-324.
3. Cassano G.B., Jori M.C. Efficacy and safety of amisulpride 50mg versus paroxetine 20mg in major depression: a randomized, double-blind, parallel group study. Int. Clin. Psychopharmacol. 2002, 17:27-32.
4. Pardini M., Guida S., Primavera A., Krueger F., Cocito L., Gialloreti L.E. Amisulpride vs. fluoxetine treatment of chronic fatigue syndrome: a pilot study. Eur. Neuropsychopharmacol. 2011, 21:282-286.
5. ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Photostability Testing of New Drug Substances and Products, Q1B 1996.
6. ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Stability Testing of New Drug Substances and Products, Q1A 2003.
7. Aman W., Thoma K. The influence of formulation and manufacturing process on the photostability of tablets. Int. J. Pharm. 2002, 28:33-41.
8. Tønnesen H.H. Formulation and stability testing of photolabile drugs. Int. J. Pharm. 2001, 225:1-14.
9. Clothier R.H. Phototoxicity and acute toxicity studies conducted by the FRAME Alternatives Laboratory: a brief review. Altern. Lab. Anim. 2007, 35:515-519.
10. Moulin A., Truffer D., Rauch-Desanti C., Istin M., Grognet J.M., Dufour A. Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma. Eur. J. Drug Metab. Pharmcokinet. 1991, 3:507-512.
11. Bohbot M., Doare L., Diquet B. Determination of a new benzamide, amisulpride [4-amino-N-(1-ethylpyrrolidin-2-ylmethyl)-5-(ethylsulphonyl)-2-methoxybenzamide], in human plasma by reversed-phase ion-pair high-performance liquid chromatography. J. Chromatogr. 1987, 416:414-419.
12. Frahnert C., Rao M.L., Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J. Chromatogr. B 2003, 794:35-47.
13. Sachse J., Hartter S., Weigmann H., Hiemke C. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J. Chromatogr B. 2003, 784:405-410.
14. Pehourcq F., Ouariki S., Begaud B. Rapid high-performance liquid chromatographic measurement of amisulpride in human plasma: application to manage acute intoxication. J. Chromatogr. B 2003, 789:101-105.
15. Tracqui A., Kintz P., Mangin P. Systematic toxicological analysis using HPLC/DAD. J. Forensic Sci. 1995, 40:254-262.
16. Ascalone V., Ripamonti M., Malavasi B. Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. Application to pharmacokinetics. J. Chromatogr. B 1996, 676:95-105.
17. Malavasi B., Locatelli M., Ripamonti M., Ascalone V. Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid-liquid extraction or solid-phase extraction in combination with high-performance liquid chromatography and fluorescence detection. Application to pharmacokinetics. J. Chromatogr. B 1996, 676:107-115.
18. Bergemann N., Kopitz J., Kress K.R., Frick A. Plasma amisulpride levels in schizophrenia or schizo affective disorder. Eur. Neuropsychopharmacol. 2004, 14:245-250.
19. Mercolini L., Mandrioli R., Amore M., Raggi M.A. Simultaneous HPLC-F analysis of three recent antiepileptic drugs in human plasma. J. Pharm. Biomed. Anal. 2010, 53:62-67.
20. Chatterjee B., Das A., Chakraborty U.S., Bhaumik U., Sengupta P., Pal T.K. HPLC method for quantification of amisulpride in human plasma. J. Biotechnol. 2008, 3:235-238.
21. Geschwend M.H., Arnold P., Ring J., Martin W. Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. J. Chromatogr. B 2006, 831:132-139.
22. Kratzsch C., Peters F.T., Kramer T., Weber A.A., Maurer H.H. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J. Mass Spectrom. 2003, 38:283-295.
23. Özkan S.A., Uslu B., Sentürk Z. Electroanalytical characteristics of amisulpride and voltammetric determination of the drug in pharmaceuticals and biological media. Electroanalysis 2004, 16:231-237.
24. Skibiński R., Komsta Ł., Hopkała H., Suchodolska I. Comparative validation of amisulpride determination in pharmaceuticals by several chromatographic, electrophoretic and spectrophotometric methods. Anal. Chim. Acta 2007, 590:195-202.
25. Grobelny P., Viola G., Vedaldi D., Dall'Acqua F., Gliszczyńska-Świgło A., Mielcarek J. Photostability of pitavastatin-a novel HMG-CoA reductase inhibitor. J. Pharm. Biomed. Anal. 2009, 50:597-601.
26. Breier A.R., Nudelman N.S., Steppe M., Scherman Schapoval E.E. Isolation and structure elucidation of photodegradation products of fexofenadine. J. Pharm. Biomed. Anal. 2008, 46:250-257.
27. Lambropoulou D.A., Hernando M.D., Konstantinou I.K., Thurman E.M., Ferrer I., Albanis T.A., Fernandez-Alba A.R. Identification of photocatalytic degradation products of bezafibrate in TiO(2) aqueous suspensions by liquid and gas chromatography. J. Chromatogr. A 2008, 1183:38-48.